Saturday, September 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· February 20, 2026

F&G signals shift toward 25% fee-based earnings by 2028 while expanding AUM and capital flexibility

View original at seekingalpha.com
F&G signals shift toward 25% fee-based earnings by 2028 while expanding AUM and capital flexibility Earnings Call Insights: F&G Annuities & Life, Inc…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • FNF distribution strengthens F&G's positioning within equity markets and facilitates greater institutional ownership

    80% confidence
  • F&G feels comfortable and confident in the credit soundness of the investment portfolio

    80% confidence
  • Starting Q1 2026, F&G is updating long-term expected return for alternative investments to reflect only 40% or $4 billion of equity interest, with no impact to adjusted net earnings on an as-reported basis

    80% confidence
  • F&G plans for continued mediocre returns as the prudent approach

    80% confidence
  • F&G has a blended return of approximately 10% on current basis, with quarterly return in the 7% to 7.5% range

    80% confidence
  • Operating expense ratio expected to improve to approximately 45 basis points by year-end 2027 for a cumulative 15 basis points or 25% improvement over the 3-year period

    80% confidence
  • The Ancient Financial Holdings transaction offers counterparty diversification for MYGA flow reinsurance in the future

    80% confidence
  • F&G is trading at $0.62 of book value and the stock is trading as though there are billions of credit losses coming

    80% confidence
  • Fee-based earnings are expected to reach approximately 25% of total earnings by year-end 2028

    80% confidence
  • $200 million of the $300 million proceeds have already been included in RBC number at year-end, with another $100 million to come for general uses including sales growth and AUM growth

    80% confidence
  • F&G delivered a strong finish to an outstanding year through disciplined growth and proven business model flexibility, transitioning to be more fee-based, higher margin and less capital intensive

    80% confidence
  • Annuity terminations are a potential source of quarterly variability as F&G moves into 2026

    80% confidence
  • If surrenders come down when F&G has more assets, the company would rather have the assets even if it meant less expansion of ROA

    80% confidence
  • Software exposure is less than 5% of the total portfolio, with less than 1% having disruption risk

    80% confidence
  • F&G will continue to write MYGA but will be more selective about it due to significant fluctuation in demand

    80% confidence
  • F&G expects to receive net proceeds of approximately $300 million from the sale of F&G Life Re Limited legal entity and runoff in-force block

    80% confidence
  • F&G will pull fixed costs down a few percent to fund variable costs while continuing to grow without growing expenses

    80% confidence
  • F&G feels very confident in what's in the investment portfolio

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com